Individualizing therapy for early, middle-of-the-night and late-night insomnia

International Journal of Clinical Practice, Supplement

Volumn , Issue 116, 2001, Pages 20-24

  Scharf, M B ^a  

^a Ctr for Research in Sleep Disorders   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLURAZEPAM; HYPNOTIC AGENT; PLACEBO; ZALEPLON;

AMNESIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; FATIGUE; HUMAN; INSOMNIA; MULTICENTER STUDY; NORMAL HUMAN; PERFORMANCE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; REVIEW; SLEEP DISORDER; SLEEP PATTERN; TREATMENT PLANNING;

ACETAMIDES; ADOLESCENT; ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PLACEBOS; PYRIMIDINES; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 33745071294     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Insomnia and its treatment. Prevalence and correlates
2. Characteristics of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. I
3. Sleep complaints among elderly persons: An epidemiologic study of three communities
4. Psychotropic drug use and the risk of hip fracture
5. Benzodiazepine use and the risk of motor vehicle crash in the elderly
6. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects
7. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo
8. Efficacy and tolerability of 14-day administration of zaleplon 5mg and 10mg for the treatment of primary insomnia
9. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic
10. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening
11. Evaluation of next-day functioning and residual sedation in healthy subjects: Zaleplon vs. flurazepam
12. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance
13. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance
14. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia
15. Guidelines for the multiple sleep latency test (MSLT): A standard measure of sleepiness
16. Insomnia
17. Nonpharmacological interventions for insomnia: A meta-analysis of treatment efficacy